FDA Approvals, News & UpdatesSkin Cancer

Libtayo Approved for Some Patients with Basal-Cell Carcinoma

The immunotherapy Libtayo is a new treatment option for advanced or metastatic basal-cell carcinoma, a type of skin cancer. Libtayo was initially approved for a different type of skin cancer.
April 2021 Vol 7 No 2

In February 2021, the FDA approved a new indication for Libtayo (cemiplimab; from Regeneron/sanofi-aventis), a PD-1 inhibitor, for the treatment of patients with locally advanced or metastatic (spreading) basal-cell carcinoma, a type of skin cancer, who had received a hedgehog inhibitor or are not eligible for that type of drug.

Libtayo was previously approved by the FDA for patients with metastatic or locally advanced cutaneous squamous-cell carcinoma, a different type of skin cancer.

This new FDA approval was based on results from Study 1620 of 84 patients with locally advanced basal-cell carcinoma and 28 patients with metastatic basal-cell carcinoma.

The objective response rate was 29% in patients with locally advanced basal-cell carcinoma, and 79% of the patients maintained their response for 6 months or longer. Among the patients with metastatic basal-cell carcinoma, the objective response rate was 21%; all the responders maintained their response for 6 months or longer.

The most common side effects were fatigue, musculoskeletal pain, diarrhea, rash, and pruritus. Severe adverse reactions included pneumonitis, hepatitis, colitis, adrenal insufficiency, hypothyroidism and hyperthyroidism, diabetes, and nephritis.

Share this:

Recommended For You
Breast CancerFDA Approvals, News & Updates
Drug Watch: Recently FDA-Approved Breast Cancer Treatments
There are more treatment options available for breast cancer than ever before – and more are coming. Here’s an overview of the most recently approved medicines.
Skin CancerPatient Stories
Climate Change Plays Havoc on Weather Patterns, and on Skin Cancer Rates
By Mark T. Ryan, RN
Mark Ryan, RN, is not worried about the impact of climate change on the weather, but on skin cancer, which he knows first-hand. A decrease in stratospheric ozone requires stringent environmental regulations to prevent cancer, he says.
FDA Approvals, News & UpdatesLymphoma
FDA Approved Breyanzi, Novel Gene Therapy, for Large B-Cell Lymphoma
“Today’s approval represents another milestone in the rapidly progressing field of gene therapy,” said Peter Marks, MD, PhD, Director of the FDA’s Center for Biologics Evaluation and Research.
FDA Approvals, News & UpdatesLymphomaFollicular Lymphoma
FDA Approved Ukoniq, New Targeted Therapy, for Marginal-Zone and Follicular Lymphoma
Ukoniq is the first dual inhibitor of PI3K-delta and CK1-epsilon to be approved by the FDA, and is the first targeted, once-daily oral therapy option for marginal-zone or follicular lymphoma.
Last modified: April 28, 2021

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.